{"entity":{"id":"pamlectabart-tismanitin","kind":"drug","name":"Pamlectabart tismanitin","aka":["HDP-101","BCMA-ATAC"],"tldr":"Pamlectabart tismanitin is an experimental antibody-drug conjugate with an amanitin payload from Heidelberg Pharma, in phase 2 trials for relapsed or refractory multiple myeloma.","summary":"Pamlectabart tismanitin (HDP-101, BCMA-ATAC) is an antibody-drug conjugate with an amanitin payload (ATAC) from Heidelberg Pharma, with Hangzhou Zhongmei Huadong Pharmaceutical as partner. An antibody-drug conjugate in which a BCMA antibody delivers the toxin amanitin to myeloma cells. Its furthest stage is phase 2, for relapsed or refractory multiple myeloma. ClinicalTrials.gov registers it in 2 studies linked below. Phase I part completed early April 2026; phase IIa dose expansion started (company page). FDA Fast Track Oct 2025, orphan designation March 2024. Whether it works in people has not been established unless a trial below reports it.","status":"phase-2","asOf":"2026-11-03","links":[{"label":"Heidelberg Pharma: heidelberg-pharma.com","url":"https://heidelberg-pharma.com/en/research-development/atac-r-projects"},{"label":"Heidelberg Pharma: heidelberg-pharma.com","url":"https://heidelberg-pharma.com/en/research-development/atac-r-projects"},{"label":"Heidelberg Pharma: heidelberg-pharma.com","url":"https://heidelberg-pharma.com/en/research-development/atac-r-projects"},{"label":"Heidelberg Pharma: clinicaltrials.gov","url":"https://clinicaltrials.gov/api/v2/studies/NCT07529782"},{"label":"ClinicalTrials.gov: trials of HDP-101","url":"https://clinicaltrials.gov/search?intr=HDP-101"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["myeloma-relapsed-refractory"],"sections":[],"technologies":[],"targets":["bcma"],"drugs":[],"companies":["heidelberg-pharma"],"institutions":[],"pathways":[],"terms":[],"trials":["nct04879043","nct07529782"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"provenance":{"editedBy":"OnCo gap audit, class 5 (company pipeline pages and ClinicalTrials.gov v2)","editedOn":"2026-11-03"},"code":"HDP-101","modality":"Antibody-drug conjugate with an amanitin payload (ATAC)","mechanism":"An antibody-drug conjugate in which a BCMA antibody delivers the toxin amanitin to myeloma cells.","approvals":[],"mechanismSteps":[],"toxicity":[],"access":[],"regulatoryEvents":[]},"route":"/drugs/pamlectabart-tismanitin/","neighbours":{"cancer":[{"id":"myeloma-relapsed-refractory","kind":"cancer","name":"Relapsed or refractory multiple myeloma","route":"/cancers/myeloma-relapsed-refractory/"}],"target":[{"id":"bcma","kind":"target","name":"BCMA","route":"/targets/bcma/"}],"company":[{"id":"heidelberg-pharma","kind":"company","name":"Heidelberg Pharma","route":"/companies/heidelberg-pharma/"}],"trial":[{"id":"nct07529782","kind":"trial","name":"Study to Assess Safety and Efficacy of HDP-101 in Chinese Patients With Relapsed or Refractory Multiple Myeloma","route":"/trials/nct07529782/"},{"id":"nct04879043","kind":"trial","name":"Study to Assess Safety of HDP-101 in Patients With Relapsed Refractory Multiple Myeloma","route":"/trials/nct04879043/"}]}}